Back to all research

Ipamorelin: What the Research Says

July 7, 2026

Ipamorelin is frequently discussed within the family of growth-hormone secretagogues. This overview summarizes what the published preclinical literature reports, strictly within a laboratory-research context.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and a member of the growth-hormone-releasing-peptide (GHRP) family. In research it is characterized as a selective agonist of the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a) — the same receptor targeted by GHRP-2, GHRP-6, and the non-peptide ibutamoren. It emerged from medicinal-chemistry work on a series of highly potent GHRPs.

Mechanisms Studied in Research

  • GHS-R1a agonism. By mimicking ghrelin at GHS-R1a, ipamorelin has been studied for its association with growth-hormone release from the pituitary in cell and animal assays.
  • Reported selectivity. In preclinical work, ipamorelin is described as releasing GH with high potency while, relative to some other secretagogues, showing comparatively limited effects on other pituitary hormones.
  • Pharmacokinetics. Preclinical PK studies reported a systemic clearance roughly 5-fold lower than GHRP-6, with the peptide mainly recovered in urine and moderate resistance to metabolism.

Areas of Preclinical Investigation

Beyond GH-release assays in rat pituitary cells and anesthetized rats, ipamorelin has been examined in rodent models such as post-operative ileus (gastrointestinal transit). These are animal and in-vitro models used to probe biology, not demonstrations of human benefit.

The State of the Evidence

  • Preclinical. The published record is largely mechanistic and animal-based; comprehensive human efficacy trials are lacking.
  • Regulatory status. Ipamorelin is not an FDA-approved drug. Research-grade material is supplied for laboratory research use only.

Key Takeaways

  • Ipamorelin is a synthetic pentapeptide and selective GHS-R1a (ghrelin receptor) agonist.
  • Research has focused on GH-release potency, selectivity, and pharmacokinetics in animal models.
  • It is not FDA-approved and is offered strictly for laboratory research.

References

  • Raun K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” Related series: “A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.” PMID 9733495.
  • “Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.” PMID 9879640.
  • “Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus.” ScienceDirect.

Research Use, Legal Status & Handling

Material supplied for research is intended for in-vitro laboratory research use only. It is not a dietary supplement, drug, cosmetic, or food. Where an approved pharmaceutical version of a compound exists, research-grade material is not that approved product and is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws and regulations in their jurisdiction. Research peptides are generally stored lyophilized, protected from light and heat, with reconstitution and handling performed per standard laboratory protocols.

Disclaimer: This article is provided for educational and informational purposes only and summarizes published laboratory and, where noted, clinical research. It is not medical advice or a recommendation for any form of use. Research-grade material is intended strictly for in-vitro research use only — not for human or veterinary consumption. Always consult a qualified professional regarding health-related questions.